West Pharmaceutical Services (NYSE:WST) Releases FY 2024 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.550-6.750 for the period, compared to the consensus estimate of 6.510. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion. West Pharmaceutical Services also updated its FY24 guidance to $6.55 to $6.75 EPS.

West Pharmaceutical Services Stock Up 15.4 %

Shares of WST traded up $44.21 during midday trading on Thursday, hitting $330.65. The stock had a trading volume of 1,983,070 shares, compared to its average volume of 558,379. The company has a 50 day simple moving average of $299.60 and a two-hundred day simple moving average of $322.81. West Pharmaceutical Services has a twelve month low of $265.00 and a twelve month high of $413.70. The firm has a market cap of $23.99 billion, a price-to-earnings ratio of 47.03, a price-to-earnings-growth ratio of 10.21 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. During the same period in the prior year, the business earned $2.11 EPS. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. On average, analysts anticipate that West Pharmaceutical Services will post 6.42 EPS for the current year.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.